fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Ipratropium bromide

All products: Limited Use (codes 265, 266, 267, 268)

Teva-Ipratropium Sterinebs · DIN 02216221 · 250 mcg/mL · Inh Sol-2mL UDV Pk

Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Ipratropium Sterinebs · DIN 02216221 Manufacturer: Teva Canada Limited; listing date 1999-09-15 Health Canada: Marketed since 2012-07-12 · brand TEVA-IPRATROPIUM STERINEBS · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Ipratropium Sterinebs: Formulary list price $1.32 per unit (the source does not state the unit; exact figure $1.3180). What the ministry pays, not the patient.

Ministry pays: $1.3180 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02216221)

Source record
DIN 02216221: Teva-Ipratropium Sterinebs Raw flags: sec12=Y, sec3=Y Item: 120800046; group id 206; item number 0376; lccId 00031; manufacturer id TEV Source form: Inh Sol-2mL UDV Pk; strength: 250mcg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.3180; ministry $1.3180 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02216221 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43176
Interchangeable products
Atrovent UDV · DIN 01950681 · not recorded PMS-Ipratropium · DIN 02231245 · $1.3180 Ratio-Ipratropium UDV · DIN 02097168 · $1.3180
Shortage status: resolved shortage (ended June 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02216221
Shortage record checked October 6, 2026

Other products in the same Health Canada class (R03BB): coverage varies; not interchangeable

  • Aclidinium (Tudorza Genuair): general benefit
  • Glycopyrronium (Seebri Breezhaler): general benefit
  • Tiotropium (Spiriva): general benefit
  • Umeclidinium (Incruse Ellipta): general benefit
Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered

Matched class: 12:08 Parasympatholytic (Cholinergic Blocking) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM Some products covered without a code (check the product listing): OXYBUTYNIN CHLORIDE, TRIHEXYPHENIDYL HCL 12:08 Parasympatholytic (Cholinergic Blocking) Agents

ACLIDINIUM BROMIDE

· 1 products · General benefit · strengths: 400mcg/actuation · Pd Inh-60 Dose Pk

GLYCOPYRRONIUM BROMIDE

· 1 products · General benefit · strengths: 50mcg · Inh Pd-Cap

BENZTROPINE MESYLATE

· 1 products · General benefit · strengths: 1mg · Tab

ETHOPROPAZINE HCL

· 1 products · General benefit · strengths: 50mg · Tab

OXYBUTYNIN CHLORIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1mg/mL, 5mg · O/L, Tab

PROCYCLIDINE HCL

· 1 products · General benefit · strengths: 2.5mg · Tab

TRIHEXYPHENIDYL HCL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 2mg, 5mg · Tab

HYOSCINE BUTYLBROMIDE

· 2 products · Limited Use, codes 481 · strengths: 10mg · Tab

IPRATROPIUM BROMIDE/SALBUTAMOL

· 3 products · Listed, not a benefit (1), Limited Use, codes 256, 257, 258, 259 (2) · strengths: 500mcg/2.5mg/2.5mL · Inh Sol-2.5mL Amp Pk

SCOPOLAMINE HYDROBROMIDE

· 4 products · Listed, not a benefit (2), Limited Use, codes 481 (2) · strengths: 0.4mg/mL, 0.6mg/mL · Inj Sol (Preservative Free)

FLAVOXATE HCL

· 2 products · Listed, not a benefit · strengths: 200mg · Tab

TRIMEBUTINE MALEATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:08 and 5 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS AA-IPRAVENT (ipratropium bromide inhalation solution) is indicated for: • the treatment of bronchospasm associated with acute exacerbations of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. • the treatment of bronchospasm associated with acute severe exacerbations of bronchial asthma when used in conjunction with a beta2 adrenergic agonist such as salbutamol. AA-IPRAVENT inhalation solution must be administered by means of nebulizer using gas flow (oxygen or compressed air). 1.1 Pediatrics Pediatrics (<5 years of age): Based on the data reviewed by Health Canada, the efficacy and safety of AA-IPRAVENT in children younger than 5 years have not been established. 1.2 Geriatrics Geriatrics (≥65 years of age): Elderly patients can use AA-IPRAVENT at the recommended dose. https://pdf.hres.ca/dpd_pm/00072339.PDF PM date: AUG 12, 1994 Source product: AA-IPRAVENT; DIN 02126222; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.